More Post from the Author
- Families Turn to Experts as Dementia Cases Rise
- Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight
- ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM
- WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES
- RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing
Invitation to presentation of Essity's interim report for quarter 1, 2025
STOCKHOLM, March 24, 2025 /PRNewswire/ -- The hygiene and health companyEssity will publish its interim report for quarter 1, 2025 on April 24 at approximately 07:00CET. President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET the same day.
Link to the live webcast and teleconference, which can also be viewed afterwards: https://essity.videosync.fi/2025-04-24-q1
Contact information for conference call with the possibility to ask questions:
UK: +44 (0) 33 0551 02 00
USA: +1 786 697 35 01
SWE: +46 (0)8 505 204 24
Please call in well in advance of the start of the presentation. Indicate: "Essity".
For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 73 313 30 55, [emailprotected]
Sandra berg, Vice President Investor Relations, +46 70 564 96 89, [emailprotected]
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Invitation to presentation of EssityEURs interim report for quarter 1, 2025 | |
https://news.cision.com/essity/i/quarter-1-2025-invitation,c3388529 | Quarter 1 2025 invitation |

More Post from the Author
- Families Turn to Experts as Dementia Cases Rise
- Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight
- ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM
- WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES
- RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing